AeroLEF®
AeroLEF® is a proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl in development for the treatment of moderate to severe acute pain. It is delivered through commercially available breath-actuated nebulizers and is designed to enable each patient to rapidly achieve analgesia and select the appropriate dose for each pain episode.
In contrast to fixed-dose approaches to opioid delivery, where a significant titration period is often required to determine the suitable dose for a patient, AeroLEF is being developed as a non-invasive delivery system designed to enable patients to self-titrate. Using AeroLEF, patients can identify and select a personalized dose for each pain episode, achieving both rapid onset and extended duration of analgesia.
Read more about AeroLEF's variable dosing.
Browse scientific publications on AeroLEF.
Clinical trials with AeroLEF
AeroLEF has completed several Phase I and II studies in acute pain. Phase III studies are being planned.
Availability of AeroLEF
AeroLEF is available through participation in clinical trials.